Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC

Clinical trial NCT05096390 · UNKNOWN

Trial details

NCT number: NCT05096390
Sponsor: Centre Leon Berard
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Papillary Renal Cell Carcinoma Type 2

Start date: 2022-06-01
Primary completion: 2024-10-01
Enrollment: 72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.